A Phase II Study of MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Nov 2017
At a glance
- Drugs Durvalumab (Primary)
- Indications Brain metastases; Non-small cell lung cancer; Solid tumours
- Focus Therapeutic Use
- 21 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 12 Sep 2016 Status changed from not yet recruiting to recruiting.
- 27 May 2016 Planned End Date changed from 1 Oct 2021 to 1 Dec 2021.